Supplements and blood sugar: what is established – and what is not

The preliminary point that frames everything else

In law, food supplements are foods, not medicines. That has a consequence many people underestimate: efficacy, safety and quality are not checked by any authority before sale – responsibility rests solely with the manufacturer.³ A product on the shelf is therefore no reliable proof that it works.

The second point follows from the first: a preparation that explicitly advertises lowering blood sugar in type 2 diabetes would, on that logic, be a medicine and subject to approval.³ That is why the packaging says something else – usually an authorised standard sentence about a mineral it contains. Once you have grasped that, you read labels differently.

Four routes by which a substance can affect blood sugar at all

Before judging individual substances, it helps to look at the mechanics. There are essentially four points of attack – and every promise should map onto one of them.

The overview: sorted by research

The detailed overview: 32 substances and what sits behind them

The table below is the reference section of this article. For each substance it gives the mechanism, the grading by research and the point I consider most important. Deliberately without quantities: dosage belongs in a medical consultation, not on a website.

Group 1: what is legally underpinned

For a small number of substances the EU has authorised health claims. That list sits in Regulation (EU) No 432/2012 and is exhaustive: whatever is not on it may not be advertised.¹ For blood sugar, these are essentially the following.

Beta-glucan is worth a closer look, because a widespread misunderstanding sits here. The condition of 4 g per 30 g of available carbohydrate cannot be met with ordinary oat or barley products; that requires enriched preparations.⁵ This does not mean porridge is pointless: the grain matrix itself acts favourably on the curve. It only means the advertised effect is tied to an amount that a normal portion does not deliver.

With chromium a second point applies. The claim is authorised, which is precisely why chromium appears in many preparations aimed at people with diabetes. For Germany, however, there is no indication of inadequate chromium status in the population.² Where there is no deficiency, no additional benefit is to be expected from additional intake – that is the fourth route in Figure 1, and it only works if something is genuinely lacking.

Group 2: where studies show a signal – with limitations

Berberine is the substance with the most striking data. A systematic review of 14 randomised trials with 1,068 participants found clear effects on glucose and lipid values when combined with lifestyle measures; against oral antidiabetic drugs, however, berberine was not superior.⁶ A more recent meta-analysis of nine trials with 547 patients found fasting glucose down by roughly 15 mg/dl and HbA1c by about 0.3 percentage points.⁷

The caveat sits in the same papers: methodological quality was largely low, the trials were short, small and overwhelmingly from one region.⁶ On top of that, berberine acts on liver metabolism and can therefore alter how other medicines are broken down. There is no authorised EU claim for berberine – advertising with one would be unlawful.

Soluble fibre – psyllium, glucomannan, pectin, beta-glucan – is the mechanically most plausible case: it forms a gel in the gut and slows sugar absorption. That is the same route that a fibre-rich meal takes anyway, and for several of these substances the effect is even authorised as a claim. The honest question here is less „does it work?“ than „why as a powder, when it is already in the food?“.

Magnesium is associated with insulin resistance – people with a low intake more often show poorer insulin action in observational data. That is a correlation, not a proven cause. Supplementation becomes sensible where a deficiency genuinely exists and has been established medically. Alpha-lipoic acid has better data for neuropathic symptoms than for glucose values themselves. Myo-inositol is studied mainly in the context of PCOS and gestational diabetes – a separate setting that does not transfer to type 2 diabetes.

Group 3: where the research does not hold

Cinnamon is the best-known example – and the clearest. The German consumer advice centre concludes that there is no research of effect for cinnamon preparations and that studies show no impact on the long-term value HbA1c.⁴ Blood-sugar claims on such products generally do not refer to the cinnamon at all, but to added chromium or zinc.⁴

For botanical substances as a whole – bitter melon, gymnema, fenugreek and others – a particular situation applies: health claims on plant constituents have still not been finally assessed and remain on hold.¹⁰ As long as that is the case, there is no authorised statement for them to rely on.

Vitamin D deserves its own assessment, because expectations here run especially high. The largest prevention trial to date found a 12 percent lower diabetes risk in people with prediabetes – not statistically significant.⁹ A meta-analysis measuring insulin sensitivity with the methodological gold standard found no favourable effect.¹¹ A proven vitamin D deficiency is a different question, to be settled medically – but as a blood-sugar strategy, vitamin D does not hold up on current data.

The risks that rarely get discussed

The most important point concerns everyone already under treatment: a substance that lowers blood sugar lowers it on top of the existing medication. With insulin or sulfonylureas that can lead into hypoglycaemia. This is not a theoretical risk; it is the reason every preparation belongs in medical hands first.

How I place this for myself

I take no preparation that promises me better blood sugar values. Not on principle, but because I can see what actually moves the needle for me: movement after eating, fibre in the meal rather than in a capsule, and timing. Those three levers are visible in my CGM data – and they cost nothing.

This is explicitly not a recommendation against supplements. A proven deficiency is a good reason for targeted supplementation, and that decision belongs in a conversation with your doctor, backed by lab values. What I reject is something else: the idea that a capsule could replace the work that makes the difference.

What I check on the next label